{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-070007","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.774780+00:00","generated_at":"2026-06-27T00:26:45.702556+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prelude appoints Jane Huang as President & CMO; updates pipeline prioritizing PRT811 and IV PRT1419","bullets":["Appoints Jane Huang President & CMO effective April 4, 2022; compensation: $525k base, 50% bonus target, 150k RSUs, 460k options.","Prioritizes PRT811 over PRT543 for PRMT5 program due to superior safety & brain penetration; expansion cohort data in 2H2022.","New pipeline candidate PRT3645, a highly brain-penetrant CDK4/6 inhibitor; IND submission planned mid-2022.","IV formulation of MCL1 inhibitor PRT1419 prioritized; combination trial with venetoclax starts mid-2022; RP2D by 2H2022.","SMARCA2/BRM degrader progress; IND submission planned by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-070007","json":"https://secwatch.observer/filing/0001193125-22-070007.json","markdown":"https://secwatch.observer/filing/0001193125-22-070007.md","text":"https://secwatch.observer/filing/0001193125-22-070007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/0001193125-22-070007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/d641589d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:26:45.702556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f3c5a27d1","claim":"Jane Huang was appointed as President and Chief Medical Officer at Prelude Therapeutics Inc.","evidence_excerpt":"the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/0001193125-22-070007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}